🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

14 recruiting trials

for Antiphospholipid Syndrome (APS)

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site📍 Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients NCT07372170n/a2 sites📍 Madrid📍 Madrid Infanta Leonor University Hospital Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study NCT00616317n/a1 site📍 Sacramento University of California, Davis Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS NCT05646394n/a3 sites📍 Buenos Aires📍 Córdoba📍 Hamilton McMaster University · Tests: Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity, Vitamin K antagoni… Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) NCT06371417Phase 177 sites📍 Orange📍 Baltimore📍 Lake Success Chugai Pharmaceutical · Tests: RAY121 International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants NCT04262492n/a1 site📍 Nancy Stéphane Zuily · Tests: Rivaroxaban Follow-up Cohort of Patients With Antiphospholipid Syndrome NCT07178925n/a1 site📍 Rouen University Hospital, Rouen · Tests: Study of Antiphospholipid Syndrome responding to the Sydney classification of 2006 A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases NCT07123519Phase 11 site📍 Tianjin China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Armenian NAtionwide REGistry of Systemic Autoimmune and Autoinflammatory Diseases NCT05904301n/a6 sites📍 Yerevan📍 Yerevan📍 Yerevan Santé Arménie French-Armenian Research Center · Tests: Usual medical management of patients, additional blood and stool samples for biobanking Effect of Belimumab on Antibody Titers in Primary APS Patients NCT06747312Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Belimumab+SOC, SOC IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy NCT03152058Phase 23 sites📍 New York📍 Salt Lake City📍 Toronto David Ware Branch · Tests: Certolizumab Pegol Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) NCT00198068n/a10 sites📍 Chicago📍 Chicago📍 Baltimore Hospital for Special Surgery, New York Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial) NCT07584083Phase 21 site📍 Athens National and Kapodistrian University of Athens · Tests: Anifrolumab A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases NCT07104721Phase 11 site📍 Hefei China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy